INTRODUCTION
Schizophrenia is a chronic and disabling psychiatric disorder.
The annual incidence of schizophrenia averages 15 per 100,000, and the average point prevalence is around 4.5 per population of 1000
The risk of developing schizophrenia over one's lifetime averages 0.7% Risperidone is a second generation/ atypical antipsychotic with actions on 5HT2 and D2 receptors, which is used in the treatment of schizophrenia 
OBJECTIVE
Literature search was conducted in MEDLINE, Embase, PsycINFO and CENTRAL databases All randomized controlled trials (RCTs) examining the efficacy and safety of risperidone in adult patients with Schizophrenia were included
In addition, references of the included studies were screened for additional studies Two authors independently selected papers, extracted data and assessed quality.
Primary outcome was improvement in symptom severity assessed by Positive and Negative Syndrome Scale (PANSS), PANSS positive and and PANSS negative at 12 months Secondary outcomes were Clinical Global Impressions Scale (CGIS), and adverse events.
MATERIALS AND METHODS
The change in symptom severity as assessed by PANSS positive score was comparable between Risperidone and olanzapine, (SMD -0.20, 95% CI -1.55 to 1.16; 3 RCTs, n=130) Risperidone was associated with significantly better improvement in symptom severity than quetiapine, as assessed by PANSS positive score (SMD -2.37, 95% CI -2.87 to -1.86; 2 RCTs, n = 107)
The change in symptom severity as assessed by PANSS total score was comparable between Risperidone and olanzapine, [standard mean difference (SMD) = -0.24, 95% confidence interval (CI) -0.59 to 0.11; 3 RCTs, n=130] The change in symptom severity as assessed by PANSS total score was comparable between Risperidone and quetiapine, (SMD = -2.53, 95% CI -6.50 to 1.44; 2 RCTs, n = 107)
DISCUSSION
The typical manifestations of schizophrenia include positive and negative symptoms:
Positive symptoms refer to an excess or distortion of normal functions, and include fixed, false beliefs (delusions) and perceptions without cause (hallucinations),
Negative symptoms represent a diminution or loss of normal functions, and include apathy and lack of drive, disorganisation of behaviour and thought, and catatonic symptoms such as mannerisms and bizarre posturing Schizophrenia typically presents in early adulthood or late adolescence
When compared to women with schizophrenia, men with schizophrenia have an earlier age of onset, and tend to experience a more serious form of the illness with more negative symptoms, less chance of a full recovery, and a generally worse outcome Schizophrenia results in significant amount of suffering and disability, with 80%-90% of patients not able to work Antipsychotic medications form the mainstay of treatment of psychotic symptoms.
The second generation (atypical) antipsychotics (risperidone, olanzapine, and clozapine) are preferred over older (typical) antipsychotics (haloperidol, chlorpromazine) because of their lower incidence of extrapyramidal, anticholinergic and cardiac side effects and a possible greater efficacy in reducing negative and neurocognitive symptoms
There is a dearth of studies comparing efficacy and safety of different second generation antipsychotics The change in symptom severity as assessed by CGI was comparable between Risperidone and olanzapine, (SMD 0.04, 95% CI -0.31 to 0.40; 3 RCTs, n=130) The change in symptom severity as assessed by CGI was comparable between Risperidone and quetiapine, (SMD -0.54, 95% CI -1.44 to 0.36; 3 RCTs, n = 545)
There was no significant difference in drug withdrawals between risperidone and olanzapine, (risk ratio 1.01, 95% CI 0.86 to 1.19; 7 RCTs, n=1221) or between risperidone and quetiapine (RR 1.12, 95% CI 0.62 to 2.02; 4 RCTs, n=1124)
The change in symptom severity as assessed by PANSS negative score was comparable between Risperidone and olanzapine, (SMD -0.56, 95% CI -1.23 to 0.11; 3 RCTs, n=130) The change in symptom severity as assessed by PANSS negative score was comparable between Risperidone and quetiapine, (SMD -1.52, 95% CI -4.97 to 1.93; 2 RCTs, n = 107) 
